Table 3.
Molecular and biophysical biomarkers.
| Biomarkers: median; min–max or % | CKD (n: 35) |
PE (n: 24) |
Other (n: 17) |
Statistical significance |
|---|---|---|---|---|
| sFlt-1 (pg/mL) | 1893 (585–13306) |
11184 (308–28182) |
5472 (222–15984) |
P0 < 0.001 |
|
| ||||
| PlGF (pg/mL) | 270 (11.5–1770) |
39 (10.2–330.3) |
94.4 (11.5–2564) |
P0 < 0.001 |
|
| ||||
| sFlt-1/PlGF ratio | 8.29 (1.04–137.40) |
317.32 (28.05–2619.11) |
58.96 (1.46–355.45) |
P0 < 0.001 |
|
| ||||
| Normal umbilical and uterine flow | 85.7% | 37.5% | 52.9% | P0 = 0.001 |
| Normal uterine or umbilical flow | 14.3% | 29.2% | 29.4% | |
| Abnormal umbilical and uterine flow | 0% | 33.3% | 17.6% | |
P0: CKD versus PE versus Other; P1: CKD versus PE; P2: CKD versus Other; P3: PE versus Other.
Note. Comparisons between groups: sFlt-1: P1 < 0.001; P2 = 0.004; P3 = 0.003. PlGF: P1 < 0.001; P2 = 0.002; P3 < 0.003. Ratio sFlt1-PlGF: P1 < 0.001; P2 = 0.001; P3 = 0.001; prevalence of normal flows: P1 < 0.001; P2 = 0.017; P3 = 0.508.
Presence of at least one impaired uteroplacental flow for diagnosis of PE and Other diseases versus CKD: sensitivity 56.1% (95% CI: 39.7%–71.5%); specificity 85.7% (95% CI: 69.7%–95.2%); PPV 82.1% (95% CI: 63.1%–93.9%); NPV value 62.5% (95% CI: 47.4%–76.0%).
PE only versus CKD: sensitivity 62.5% (95% CI: 40.6%–81.2%); specificity 85.7% (95% CI: 69.7%–95.2%); PPV 75% (95% CI: 50.9%–91.3%); NPV: 76.9% (95% CI: 60.7%–88.9%).